Background: There is an increasing body of evidence to support the benefits of reducing low-
density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of …

The first statin, lovastatin, was approved for commercial use in the United States almost 30
years ago on September 1, 1987. Since that time, tens of millions of individuals have been …

Statin therapy decreases low-density lipoprotein cholesterol levels and the risk of coronary
heart disease but has a considerable short-term effect on health care budgets. The cost …

Simvastatin is a potent lipid-lowering agent that has proven highly effective in the treatment
of primary hypercholesterolaemia. This report extends the data on controlled clinical trials …

It is known that plasma concentrations of rosuvastatin in east Asians are approximately
double to those in Caucasians. As a result, regulatory authorities have recommended …

Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In …

Background Although the effectiveness of statins is well established, analyses of
spontaneous adverse event reports have recently questioned the safety of rosuvastatin …

We directly compared the safety and efficacy of atorvastatin and simvastatin in
hypercholesterolemic patients. This 1-year, randomized, double-blind study was performed …

Previous work from the European Society of Cardiology (ESC), the European
Atherosclerosis Society (EAS) and from other groups has addressed the benefits of statin …

Since their introduction in 1987, statins have accumulated an extensive amount of data in
randomized clinical trials and clinical use. The studies included in the Cholesterol Treatment …